Suppression of metastatic murine ovarian cancer cells by transduced embryonic progenitor cells

Area of Science:

• Oncology
• Immunology
• Biotechnology

Background:

• Ovarian cancer remains a leading cause of gynecological cancer mortality, with advanced stages often resistant to chemotherapy.
• Current cancer immunotherapies face challenges due to the immunosuppressive tumor microenvironment, hindering treatment efficacy.
• Immune-suppressive molecules like PD-L1, Cox, and ULBP-2 in ovarian tumors impede CD8+T cell infiltration and local anti-tumor immunity.

Purpose of the Study:

• To develop an innovative immunotherapy targeting multiple ovarian cancer metastatic sites.
• To enhance CD8+T cell infiltration by modifying the local tumor environment.
• To utilize endothelial progenitor cells (EPCs) as carriers for immune-stimulatory signals.

Main Methods:

• Endothelial progenitor cells (EPCs) were genetically modified to express the chemokine CCL19, creating "immune-stimulatory EPCs".
• These modified EPCs were administered intravenously to mice with various ovarian cancer models (subcutaneous, lung metastasis, peritoneal dissemination).
• The anti-tumor effects and immune cell involvement were assessed, including comparisons with immunodeficient mouse models.

Main Results:

• Injected immune-stimulatory EPCs efficiently homed to tumor vessels in multiple metastatic models.
• A significant anti-tumor effect was observed across subcutaneous, lung, and peritoneal ovarian cancer models.
• The anti-tumor effect was dependent on the host's immune system, as it was absent in immunodeficient mice.

Conclusions:

• Engineered EPCs serve as effective carriers for delivering immune-stimulatory signals to multiple metastatic sites.
• Modifying the local tumor immune environment via EPCs shows promise for overcoming immune suppression.
• This strategy holds potential for developing future individualized cancer immunotherapies for ovarian cancer.